| 
 2012 -- H 7824  | |
| 
 =======  | |
| 
 LC01879  | |
| 
 =======  | |
| 
 STATE OF RHODE ISLAND  | |
| 
 
  | |
| 
 IN GENERAL ASSEMBLY  | |
| 
 
  | |
| 
 JANUARY SESSION, A.D. 2012  | |
| 
 
  | |
| 
 ____________  | |
| 
 
  | |
| 
 A N A C T  | |
| 
 RELATING TO STATE AFFAIRS AND GOVERNMENT -- MEDICAID GENERIC DRUG  | |
| 
 SAVINGS  | |
| 
 
  | 
        | 
| 
 
  | 
        | 
| 
      Introduced By: Representatives Williams, and Hull  | |
| 
      Date Introduced: February 28, 2012  | |
| 
      Referred To: House Health, Education & Welfare  | |
| 
 It is enacted by the General Assembly as follows:  | |
| 
 1-1  | 
      SECTION 1. Title 42 of the General Laws entitled "STATE AFFAIRS AND  | 
| 
 1-2  | 
 GOVERNMENT" is hereby amended by adding thereto the following chapter:  | 
| 
 1-3  | 
      CHAPTER 14.7  | 
| 
 1-4  | 
 THE RHODE ISLAND MEDICAID GENERIC DRUG COMPETITION AND SAVINGS ACT  | 
| 
 1-5  | 
      42-14.7-1. Short title. – This act shall be known and may be cited as the “Medicaid  | 
| 
 1-6  | 
 Generic Drug Competition And Savings Act.”  | 
| 
 1-7  | 
      42-14.7-2. Definitions. – As used in this chapter:  | 
| 
 1-8  | 
      (1) “Medicaid” means the Medicaid program, established in title XIX of the social  | 
| 
 1-9  | 
 security act, which provides medical benefits to groups of low-income people. In this chapter,  | 
| 
 1-10  | 
 “Medicaid” refers to the state Medicaid program managed by the state of Rhode Island.  | 
| 
 1-11  | 
      (2) “Generics” or “generic drugs” means copies of brand name drugs that are no longer  | 
| 
 1-12  | 
 protected by patents. Generics are drugs that contain the same active ingredient, are identical in  | 
| 
 1-13  | 
 strength, dosage form, and route of administration as the brand name innovator drug and has the  | 
| 
 1-14  | 
 same indications, dosing, and labeling and provides the same efficacy and safety profile to  | 
| 
 1-15  | 
 patients as the brand name innovator drug.  | 
| 
 1-16  | 
      (3) “Generic manufacturers” means manufacturers, both domestic and international, that  | 
| 
 1-17  | 
 manufacture generic drugs and distribute those generics throughout the state through various  | 
| 
 1-18  | 
 distribution systems.  | 
| 
 2-19  | 
      (4) “Competitive bidding” means a transparent procurement method in which bids from  | 
| 
 2-20  | 
 generic manufacturers are invited by openly advertising the scope, specifications, and terms and  | 
| 
 2-21  | 
 conditions of the proposed contract as well as the criteria by which the bids will be evaluated. The  | 
| 
 2-22  | 
 objective of competitive bidding is obtaining goods at the lowest prices by stimulating  | 
| 
 2-23  | 
 competition, and by preventing favoritism.  | 
| 
 2-24  | 
      42-14.7-3. Findings. – The general assembly hereby finds and declares that:  | 
| 
 2-25  | 
      (1) With every prescription filled with a generic, the consumer receives the same  | 
| 
 2-26  | 
 medicine as the brand name, with the same quality and same result, but at a much lower cost.  | 
| 
 2-27  | 
      (2) For more than twenty-five (25) years, America’s generic pharmaceutical industry has  | 
| 
 2-28  | 
 been providing the food and drug administration (FDA) approved generic versions of brand name  | 
| 
 2-29  | 
 medicines at a savings to consumers of thirty percent (30%) to as much as eighty percent (80%).  | 
| 
 2-30  | 
      (3) Millions of Medicaid recipients nationwide are using generics to treat a variety of  | 
| 
 2-31  | 
 medical conditions, including infection, heart disease and cancer. Generics are rigorously tested  | 
| 
 2-32  | 
 by the FDA and must prove that they are the same medicine with the same active ingredient,  | 
| 
 2-33  | 
 strength and dosage as their brand name counterpart. Today, there are thousands of generic drugs  | 
| 
 2-34  | 
 available and all are manufactured and inspected under the same strict quality guidelines as a  | 
| 
 2-35  | 
 brand.  | 
| 
 2-36  | 
      (4) For most brand name products there are multiple generics available and these generics  | 
| 
 2-37  | 
 can vary greatly in prices.  | 
| 
 2-38  | 
      (5) While the state Medicaid program has encouraged the use of generics drugs by  | 
| 
 2-39  | 
 Medicaid recipients, it has not taken advantage of the savings that could be generated by taking  | 
| 
 2-40  | 
 advantage of the competition among generic manufacturers which vary greatly in their pricing of  | 
| 
 2-41  | 
 generic drugs.  | 
| 
 2-42  | 
      42-14.7-4. Competitive bidding. – The Rhode Island department of human services shall  | 
| 
 2-43  | 
 require all generic manufacturers whose products are to be provided to Medicaid recipients to  | 
| 
 2-44  | 
 engage in a competitive bidding process created by the department of health to ensure that it is  | 
| 
 2-45  | 
 providing Medicaid recipients with quality generic products at a competitively bid cost.  | 
| 
 2-46  | 
      SECTION 2. This act shall take effect upon passage.  | 
| 
        | |
| 
 =======  | |
| 
 LC01879  | |
| 
 ========  | |
| 
 EXPLANATION  | |
| 
 BY THE LEGISLATIVE COUNCIL  | |
| 
 OF  | |
| 
 A N A C T  | |
| 
 RELATING TO STATE AFFAIRS AND GOVERNMENT -- MEDICAID GENERIC DRUG  | |
| 
 SAVINGS  | |
| 
 ***  | |
| 
 3-1  | 
      This act would require manufacturers of generic drugs provided to Medicaid recipients to  | 
| 
 3-2  | 
 engage in a competitive bidding process.  | 
| 
 3-3  | 
      This act would take effect upon passage.  | 
| 
        | |
| 
 =======  | |
| 
 LC01879  | |
| 
 =======  |